Cancer patients whose tumors show high SLFN11 expression show better chemotherapy response to PARP inhibitors, irinotecan, and temozolomide in recurrent or refractory solid tumors such as Ewing sarcoma and small cell lung cancers (SCLCs) [138,139,140]. Here, SLFN11 is linked to Ewing sarcoma.